Healthcare · Biotechnology
Price
$44.95
Market Cap
$4.9B
Employees
74
Beta
2.38
Avg Volume
3,919,428
CEO
Robert Barrow
Business Description
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-21.82
Stock Price: $44.95
EPS (Diluted): -2.06
EPS (Diluted): -2.06
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.60
Stock Price: $44.95
Total Equity: $332.33M
Shares: 89,327,608
Total Equity: $332.33M
Shares: 89,327,608
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-20.87
Market Cap: $4.90B
Total Debt: $0.00
Cash: $257.84M
EBITDA: -$178.31M
Total Debt: $0.00
Cash: $257.84M
EBITDA: -$178.31M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$938.3M
Market Cap: $4.90B
Total Debt: $0.00
Cash: $257.84M
Total Debt: $0.00
Cash: $257.84M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $44.95
Revenue: $0.00
Shares: 89,327,608
Revenue: $0.00
Shares: 89,327,608
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$166.31M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$183.79M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-102.5%
Net Income: -$183.79M
Total Equity: $332.33M
Total Equity: $332.33M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-60.4%
Operating Income: -$166.31M
Tax Rate: 0.0%
Equity: $332.33M
Total Debt: $0.00
Cash: $257.84M
Tax Rate: 0.0%
Equity: $332.33M
Total Debt: $0.00
Cash: $257.84M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
6.29
Current Assets: $419.32M
Current Liabilities: $66.70M
Current Liabilities: $66.70M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $332.33M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $332.33M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 89,327,608
Shares: 89,327,608
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$3.72
Total Equity: $332.33M
Shares: 89,327,608
Shares: 89,327,608
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.47
Operating CF: -$131.56M
CapEx: $0.00
Shares: 89,327,608
CapEx: $0.00
Shares: 89,327,608
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $44.95
Stock Price: $44.95
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$183.79M
Net Income: -$183.79M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares DFTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:44pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $3.2M | $527,000 | $0 |
| Gross Profit | $0 | $0 | -$3.2M | $-527,000 | $0 |
| Operating Expenses | $93.9M | $66.3M | $90.7M | $103.4M | $166.3M |
| Operating Income | -$93.9M | -$66.3M | -$93.9M | -$103.9M | -$166.3M |
| Net Income | -$93.0M | -$56.8M | -$95.7M | -$108.7M | -$183.8M |
| EBITDA | -$91.2M | -$52.1M | -$92.6M | -$105.9M | -$178.3M |
| EPS | $-3.40 | $-1.53 | $-2.44 | $-1.54 | $-2.06 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:44pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $133.5M | $142.1M | $99.7M | $273.7M | $257.8M |
| Total Current Assets | $137.2M | $146.1M | $103.9M | $281.6M | $419.3M |
| Total Assets | $164.0M | $170.0M | $124.5M | $302.2M | $440.1M |
| Current Liabilities | $10.4M | $17.9M | $32.2M | $38.8M | $66.7M |
| Long-Term Debt | $0 | $0 | $14.1M | $21.9M | $0 |
| Total Liabilities | $12.3M | $19.1M | $46.4M | $60.7M | $107.8M |
| Total Equity | $151.7M | $150.9M | $78.1M | $241.4M | $332.3M |
| Retained Earnings | -$137.7M | -$194.5M | -$290.2M | -$398.9M | -$582.7M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:44pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$45.8M | -$50.1M | -$64.4M | -$79.1M | -$131.6M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$45.8M | -$50.1M | -$64.4M | -$79.1M | -$131.6M |
| Acquisitions (net) | $-297,000 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $53.4M | $8.6M | -$42.4M | $174.0M | -$15.9M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 10:36pm (10h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$34.8M $34.8M – $34.8M
|
$226.4M $226.4M – $226.4M
|
$554.8M $554.8M – $554.8M
|
$936.6M $936.6M – $936.6M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$213.0M -$217.7M – -$101.4M
|
-$90.4M -$234.4M – $279.9M
|
$100.8M $100.8M – $100.8M
|
$287.8M $287.8M – $287.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:44pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | +83.3% | +100.0% |
| Operating Income Growth | +29.3% | -41.5% | -10.7% | -60.0% |
| Net Income Growth | +39.0% | -68.6% | -13.5% | -69.1% |
| EBITDA Growth | +42.9% | -77.6% | -14.4% | -68.4% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:41am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-25 | Sullivan Mark | S-Sale | 13,008.00 | $45.03 | $585,750 |
| 2026-06-25 | Roberts Brandi | S-Sale | 3,013.00 | $45.03 | $135,675 |
| 2026-06-25 | Barrow Robert | S-Sale | 29,208.00 | $45.03 | $1.3M |
| 2026-06-25 | Karlin Daniel | S-Sale | 10,035.00 | $45.03 | $451,876 |
| 2026-06-25 | Wiley Matthew T. | S-Sale | 2,867.00 | $45.03 | $129,101 |
| 2026-06-22 | Wiley Matthew T. | A-Award | 62,500.00 | $0.00 | $0 |
| 2026-06-22 | Barrow Robert | A-Award | 375,000.00 | $0.00 | $0 |
| 2026-06-22 | Sullivan Mark | A-Award | 62,500.00 | $0.00 | $0 |
| 2026-06-22 | Roberts Brandi | A-Award | 62,500.00 | $0.00 | $0 |
| 2026-06-22 | Karlin Daniel | A-Award | 100,000.00 | $0.00 | $0 |
| 2026-06-11 | CRYSTAL ROGER | A-Award | 4,666.00 | $0.00 | $0 |
| 2026-06-11 | CRYSTAL ROGER | A-Award | 19,188.00 | $24.11 | $462,623 |
| 2026-06-11 | GRYSKA DAVID W | A-Award | 4,666.00 | $0.00 | $0 |
| 2026-06-11 | GRYSKA DAVID W | A-Award | 19,188.00 | $24.11 | $462,623 |
| 2026-06-11 | Vallone Carol A | A-Award | 4,666.00 | $0.00 | $0 |
| 2026-06-11 | Vallone Carol A | A-Award | 19,188.00 | $24.11 | $462,623 |
| 2026-06-11 | Krebs Andreas | A-Award | 4,666.00 | $0.00 | $0 |
| 2026-06-11 | Krebs Andreas | A-Award | 19,188.00 | $24.11 | $462,623 |
| 2026-06-11 | Adsett Roger | A-Award | 14,620.00 | $24.11 | $352,488 |
| 2026-06-11 | Adsett Roger | A-Award | 3,555.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for DFTX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for DFTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30